{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"0.72","value":"0.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Urine samples were collected to assess urine Pro. Baseline was the latest pre-dose assessment with a non-missing value, including unscheduled visits. Change from Baseline was calculated by subtracting Baseline value from the post-dose visit value. Data for change from Baseline in urine Pro. excretion (24 hour) is presented","dispersionType":"Standard Deviation","groups":[{"description":"Participants were administered a dose of 0.12 mg/kg GSK2857916 as IV infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG000","title":"Part 1: GSK2857916 0.12 mg/kg"},{"description":"Participants were administered a dose of 0.03 milligrams per kilogram (mg/kg) GSK2857916 as intravenous (IV) infusion once every three weeks for a maximum of 16 cycles (1 cycle= 21 days).","id":"OG001","title":"Part 1: GSK2857916 0.03 mg/kg"}],"paramType":"MEAN","populationDescription":"Part 1 Population. Only those participants with data available at the specified data points were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline and Day 1 (Cycle 2)","title":"Change From Baseline in Urine Protein Excretion (24 Hour)-Part 1: GSK2857916 0.03 mg/kg and 0.12 mg/kg","type":"PRIMARY","unitOfMeasure":"Grams per day"}